Immuron Ltd — AGM Information 2015

Nov 24, 2015

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

2015 AGM PRESENTATION
----- End of picture text -----

November 2015

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Forward-Looking Statement
Certain statements made in this presentation are forward-looking statements and are based on
Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to
identify forward-looking statements.
Although Immuron believes the forward-looking statements are based on reasonable assumptions,
they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control,
including those risks or uncertainties inherent in the process of both developing and commercializing
----- End of picture text -----

2

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

Immuron Limited
Investment Highlights
Travelan sales growing in multiple
Growing OTC countries and positioned to grow further
Business with successful USA launch; No
competition
Phase II in Fatty-Liver Disease (NASH) – No
----- End of picture text -----

3

Pre-Clinical Phase 1 Phase 2 Phase 3 On Market

==> picture [125 x 84] intentionally omitted <==

Launched in multiple geographies

==> picture [425 x 203] intentionally omitted <==

----- Start of picture text -----

IMM-124E Fatty-Liver Disease (NASH)
Alcoholic Fatty-Liver Disease
IMM-124E
(ASH) (Funded by the NIH)
C-
IMM-524
Difficile
----- End of picture text -----

4

OTC

Rx

Corporate

5

Share Price Performance (July 1, 2014 – Nov 24, 2015)

NASH Recruitment Update RedChip Research Report Released Travelan US Launch Travelan China Agreement Signed

6

OTC

Rx

Corporate

7

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

FY2016
June – November Accomplishments
•
US: Redesigned label and messaging
•
US: 3 more distribution partners signed
•
WW: Multiple partnership discussions ongoing
•
Launch of Protectyn in AUS
•
Planning for launch in other markets
----- End of picture text -----

NASH

ASH

C-Difficile

8

Markets

Today

==> picture [29 x 86] intentionally omitted <==

Future

Customers

Products

9

Progress

Rationale

10

Expand and Maximize OTC Business

Execute Prioritized Rx Program

NASDAQ Listing and Careful Capital Allocation

11

THANK YOU

==> picture [721 x 271] intentionally omitted <==